Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.025
-0.175 (-7.95%)
Oct 10, 2025, 2:44 PM EDT - Market open
Relmada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Relmada Therapeutics stock have an average target of 1.00, which predicts a -50.62% decrease from the current stock price of 2.03.
Price Target: $1.00 (-50.62%)
Analyst Consensus: Hold
* Price targets were last updated on Dec 5, 2024.
Analyst Ratings
The average analyst rating for Relmada Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | -50.62% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | -50.62% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +541.98% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | -1.23% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +1,183.95% | Jun 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.97
from -2.65
EPS Next Year
-1.73
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.03 | -1.79 | |||
| Avg | -1.97 | -1.73 | |||
| Low | -1.89 | -1.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.